Gemcitabine and Vinorelbine Combination in Platinum-Sensitive Recurrent Ovarian Cancer

Ferrero, Annamaria; Logrippo, V.; Spanu, Pier Giorgio; Fuso, Luca; Perotto, Stefania; Daniele, Alberto; Zola, Paolo

doi:10.1111/igc.0b013e3181a8407e

Cited by 5 publications

(3 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most pancreatic cancer patients will exhibit disease progression and treatment provides only a slight survival advantage. Gemcitabine also has activity against other cancers including lymphomas and solid tumors such as lung, bladder and ovarian cancer [7][8][9][10].…”

Section: Gemcitabinementioning

confidence: 99%

Challenges of drug resistance in the management of pancreatic cancer

Sheikh

Walsh

Clynes

et al. 2010

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor). Only 25-30% of patients respond to this treatment and patients who do respond initially ultimately exhibit disease progression. Median survival for pancreatic cancer patients has reached a plateau due to inherent and acquired resistance to these agents. Key molecular factors implicated in this resistance include: deficiencies in drug uptake, alteration of drug targets, activations of DNA repair pathways, resistance to apoptosis, and the contribution of the tumor microenvironment. Moreover, for newer agents including tyrosine kinase inhibitors, over expression of signaling proteins, mutations in kinase domains, activation of alternative pathways, mutations of genes downstream of the target, and/or amplification of the target represent key challenges for treatment efficacy. Here we will review the contribution of known mechanisms and markers of resistance to key pancreatic cancer drug treatments.

show abstract

Section: Gemcitabinementioning

confidence: 99%

Challenges of drug resistance in the management of pancreatic cancer

Sheikh

Walsh

Clynes

et al. 2010

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

show abstract

“…These substances, alone or in combination, achieve a wide range of response rates. For example, Ferrero et al described a response rate of 49% with gemcitabine and vinorelbine in platinum-sensitive patients [5], whereas Burger et al found a response rate of 29% in a mixed resistant-sensitive population [6]. Lower response rates are seen among platinum-resistant patients with response rates of 25% [7], 21% [8], 11% [9], and even 3% [10] with doxorubicin and gemcitabine, topotecan and oxaliplatin, gemcitabine and vinorelbine, and vinorelbine in various combinations and dosages, respectively.…”

Section: Introductionmentioning

confidence: 99%

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

et al. 2017

View full text Add to dashboard Cite

BackgroundPrimary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy.Case presentationA 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy.ConclusionsRepeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-3004-8) contains supplementary material, which is available to authorized users.

show abstract

“…A number of chemotherapeutic agents are active in recurrent ovarian cancer including a combination of platinum and paclitaxel (Gonzalez-Martin 2003; Parmar 2003). Other chemotherapeutic agents with activity in recurrent ovarian cancer include topotecan, gemcitabine, Caelyx, Etoposide, Doxocycline, Docetaxel, Oxaliplatin and Bevacisamab (Avastin) (Bookman 1998; Ferrero 2009; Markman 2004; Monk 2009; Weber 2009). Newer chemotherapeutic agents have shown activity in recurrent ovarian cancer and response rates of 20 to 30% have been described (Harter 2006; Selinger 2009; Ozols 2005; Wright 2006).…”

Section: Introductionmentioning

confidence: 99%

Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer

Galaal

Naik

Bristow

et al. 2010

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Most women with advanced epithelial ovarian cancer will ultimately develop recurrent disease after completion of initial treatment with primary surgery and adjuvant chemotherapy. Secondary cytoreductive surgery may have survival benefits in selected patients. However, a number of chemotherapeutic agents are active in recurrent ovarian cancer and the standard treatment of patients with recurrent ovarian cancer remains poorly defined. Objectives To evaluate the effectiveness and safety of secondary surgical cytoreduction and chemotherapy compared to chemotherapy alone for women with recurrent epithelial ovarian cancer. Search methods We searched the Cochrane Gynaecological Cancer Group Trials Register, The Cochrane Register of Controlled Trials, (CENTRAL) Issue 1 2009, MEDLINE and EMBASE up to February 2009. We also searched registers of clinical trials, abstracts of scientific meetings, reference lists of review articles and contacted experts in the field. Selection criteria We searched for RCTs, quasi-randomised trials and non-randomised studies that compared secondary cytoreductive surgery and chemotherapy to chemotherapy alone in women with recurrent epithelial ovarian cancer. Data collection and analysis Three reviewers independently assessed whether potentially relevant studies met the inclusion criteria. No trials were found and therefore no data were analysed. Main results The search strategy identified 1431 unique references of which all were excluded on the basis of title and abstract. Authors’ conclusions We found no evidence from RCTs to inform decisions about secondary surgical cytoreduction and chemotherapy compared to chemotherapy alone for women with recurrent epithelial ovarian cancer. Ideally, a large randomised controlled trial or, at the very least, well designed non-randomised studies that use multivariate analysis to adjust for baseline imbalances are needed to compare these treatment modalities. The results of the ongoing RCT AGO-OVAR OP.4 (DESKTOP III) is awaited.

show abstract

Gemcitabine and Vinorelbine Combination in Platinum-Sensitive Recurrent Ovarian Cancer

Abstract: Gemcitabine and vinorelbine combination is effective and well tolerated in recurrent platinum-sensitive ovarian cancer. It may represent an option in the management of these patients because the chronic nature of the disease.

Cited by 5 publications

References 40 publications

Challenges of drug resistance in the management of pancreatic cancer

Challenges of drug resistance in the management of pancreatic cancer

Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer

Contact Info

Product

Resources

About